<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764244</url>
  </required_header>
  <id_info>
    <org_study_id>P030426</org_study_id>
    <secondary_id>MUL03010</secondary_id>
    <nct_id>NCT00764244</nct_id>
  </id_info>
  <brief_title>Laser Versus Vitrectomy Versus Intravitreal Triamcinolone Injection for Diabetic Macular Edema</brief_title>
  <acronym>VITRILASE</acronym>
  <official_title>VITRILASE Study: Prospective Randomized Trial Comparing the Effect of Laser, Vitrectomy and Intravitreal Triamcinolone Injection for Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular edema is the main cause of vision loss in diabetic patients. Its treatment is mainly
      based on laser photocoagulation, but has limited results. Alternative treatment are under
      investigation, such as vitrectomy and intravitreal injections of triamcinolone .The aim of
      VITRILASE is to compare the efficacy of these two treatments to laser photocoagulation for
      diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a randomized study with three arms

        -  vitrectomy

        -  repeat intravitreal triamcinolone injections

        -  laser photocoagulation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years</measure>
    <time_frame>at 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central macular thickness on Optical Coherence Tomography (OCT)</measure>
    <time_frame>at 8, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with visual gain ≥ 3 ETDRS lines</measure>
    <time_frame>8, 12 and 22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of lens opacities</measure>
    <time_frame>During the all follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of complications</measure>
    <time_frame>During the all follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results analysis according to preoperative vitreous detachment, honeycomb macular edema on fluorescein angiography</measure>
    <time_frame>at inclusion time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of visual fiends and posterior vitreous detachment</measure>
    <time_frame>At inclusion time and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients presenting an increase of 2 line or more of best corrected visual acuity on ETDRS charts</measure>
    <time_frame>after 1 year, 22 months and 24 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients presenting an decrease of 2 line or more of best corrected visual acuity on ETDRS charts</measure>
    <time_frame>after 1 year, 22 months and 24 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores ETDRS</measure>
    <time_frame>after 1 year, 22 months and 24 months of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean best corrected visual acuity during follow-up period</measure>
    <time_frame>during the all follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of retinopathy diabetic in each group</measure>
    <time_frame>during the all follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome in respect to posterior vitreal detachment (PVD) stage</measure>
    <time_frame>during the all follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PVD stage evolution during the follow-yp in laser and triamcinolone group</measure>
    <time_frame>first and last exam</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of visual field in each group</measure>
    <time_frame>inclusion and last visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal triamcinolone injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laser photocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vitrectomy</intervention_name>
    <description>Vitrectomy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal triamcinolone injections</intervention_name>
    <description>Intravitreal triamcinolone injections</description>
    <arm_group_label>2</arm_group_label>
    <other_name>- KENACORT RETARD</other_name>
    <other_name>- Triamcinolone Acetonid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser photocoagulation</intervention_name>
    <description>Laser photocoagulation</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with type 1 or type 2 diabetes

          2. Visual acuity (VA) : 0.1≤ VA &lt; 0.5 (35 ≤ ETDRS score &lt; 70)

          3. Patient with diffuse diabetic macular edema , as defined by :§ Retinal thickening
             involving the center of the macular on biomicroscopy§ AND diffuse leakage on
             fluorescein angiography .

          4. Macular thickness in the central area 1000 µm in diameter ³ 300 µm.

          5. Patient with :· Either diffuse diabetic macular edema · Or combined diffuse and focal
             diabetic macular edema with persistent diffuse macular edema 6 months after laser
             treatment of the focal edema .

          6. Systolic blood pressure ≤ 160 mmHg and diastolic blood pressure ≤ 90 mmHg.,

          7. HbA1c &lt; 10%.

        Exclusion Criteria:

          1. Patient with tractional diabetic macular edema, as defined by· A taut, thickened
             posterior hyaloid on biomicroscopy AND/OR· a thickened , highly reflective posterior
             hyaloid on OCT , partially detached from the posterior pole, and exerting a traction
             on the macula

          2. Active proliferative diabetic retinopathy (ETDRS stage 61 or more severe)

          3. Structural damage to the center of the macula in the study eye likely to preclude
             improvement in visual acuity following the resolution of macular edema, including
             atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s), or
             organized central hard exudate plaque³ 1 disk area

          4. Hypertensive retinopathy

          5. Epiretinal membrane.

          6. Rubeosis irides .

          7. Patient requiring immediate panretinal photocoagulation or panretinal photocoagulation
             performed within the past 6 months .

          8. History of chronic glaucoma in the study eye

          9. History of elevated intraocular pressure ≥30 mm Hg and/or alteration of visual field

         10. Concomitant therapy with systemic or topical ocular corticosteroids within the last 15
             days .

         11. Cataract surgery in the study eye within the past 6 months, Yttrium-Aluminum-Garnet
             (YAG) laser capsulotomy within the past 6 months,

         12. Aphakia

         13. Patient with pseudophakic macula edema

         14. Unstable medical status including glycemic control and blood pressure. Patients in
             poor glycemic control who, within the last 4 months, initiated intensive insulin
             treatment (a pump or multiple daily injections) should not be enrolled.

         15. Chronic renal failure

         16. Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale MASSIN, MD, PhD; Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pascale MASSIN</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.cicoph.org/wiki/doku.php/diabete:omcs:vitrilase</url>
    <description>information and referral</description>
  </link>
  <results_reference>
    <citation>Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, Gaudric A, Massin P. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006 Nov;142(5):794-99. Epub 2006 Sep 15.</citation>
    <PMID>16978576</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Macular edema</keyword>
  <keyword>Optical Coherence tomography</keyword>
  <keyword>VitrectomyLaser therapy</keyword>
  <keyword>Intravitreal triamcinolone injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

